Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Procedural Sedation in Children

Sponsor
Seoul National University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04820205
Collaborator
(none)
136
1
2
51.9
2.6

Study Details

Study Description

Brief Summary

In Korea, oral chloral hydrate is still widely used for pediatric procedural sedation. The primary objective of the study is to evaluate the effect of intranasal dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) on the first-attempt success rate of pediatric procedural sedation. The hypothesis of this study is that the intranasal dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) will improve the success rate of adequate pediatric procedural sedation (PSSS=1,2,3) within 15 minutes. This is a prospective, parallel-arm, single-blinded, multi-center, randomized controlled trial comparing the effect of intranasal dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) with oral chloral hydrate (50mg/kg) in pediatric patients undergoing procedural sedation. Prior to the procedure, each patient will be randomized in the control arm (oral chloral hydrate) or study arm (intranasal dexmedetomidine and ketamine).

Condition or Disease Intervention/Treatment Phase
  • Drug: Intranasal dexmedetomidine and ketamine
  • Drug: Oral chloral hydrate
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
136 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Procedural Sedation in Children: a Randomized Controlled Trial
Actual Study Start Date :
Sep 3, 2021
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: intranasal dexmedetomdine and kemtaine

Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)

Drug: Intranasal dexmedetomidine and ketamine
Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)

Active Comparator: oral chloral hydrate

Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)

Drug: Oral chloral hydrate
Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)

Outcome Measures

Primary Outcome Measures

  1. Success rate of adequate sedation (PSSS= 1,2,3) within 15 minutes % [During pediatric procedural sedation (up to 1 hour)]

    Success rate of adequate sedation (Pediatric Sedation State Scale= 1,2,3) within 15 minutes after sedative administration. %

Secondary Outcome Measures

  1. Onset time of sedation (PSSS= 0,1,2,3) (min) [During pediatric procedural sedation (up to 3 hour)]

    Onset time of sedation (Pediatric Sedation State Scale= 1,2,3) after sedative administration.

  2. Duration of sedation = Recovery time (PSSS= 4,5) (min) [During pediatric procedural sedation (up to 3 hour)]

    Pediatric Sedation State Scale= 4,5 after recovery of sedation

  3. PSSS(Pediatric Sedation State Scale, 0-5) [During pediatric procedural sedation (up to 3 hour)]

    5 Patient is moving in a manner that impedes the proceduralist and requires forceful immobilization. 4 Moving during the procedure that requires gentle immobilization for positioning. 3 Expression of pain or anxiety on face, but not moving or impeding completion of the procedure. 2 Quiet (asleep or awake), not moving during procedure, and no frown (or brow furrow) indicating pain or anxiety. 1 Deeply asleep with normal vital signs, but requiring airway intervention and/or assistance 0 Sedation associated with abnormal physiologic parameters that require acute intervention q 10min

  4. Heart rate during sedation (/min) [During pediatric procedural sedation (up to 3 hour)]

    HR(/min) at Baseline(T0), q 10min

  5. SpO2 during sedation (%) [During pediatric procedural sedation (up to 3 hour)]

    SpO2(%) by pulse oximetry at Baseline(T0), q 10min

  6. Respiratory rate during sedation (/min) [During pediatric procedural sedation (up to 3 hour)]

    RR(/min) at Baseline(T0), q 10min

  7. the incidence of PSSS=0 (Abnormal physiologic parameter that require acute intervention) % [During pediatric procedural sedation (up to 3 hour)]

    the incidence of PSSS=0 (Abnormal physiologic parameter that require acute intervention) %

  8. The incidence of respiratory intervention: Manual ventilation or Artificial airway % [During pediatric procedural sedation (up to 3 hour)]

    The incidence of respiratory intervention: Manual ventilation or Artificial airway

  9. The incidence of significant desaturation (SpO2 < 95% or -10% from baseline, >10 seconds) % [During pediatric procedural sedation (up to 3 hour)]

    The incidence of significant desaturation (SpO2 < 95% or -10% from baseline, >10 seconds) %

  10. The incidence of significant apnea (>20seconds) % [During pediatric procedural sedation (up to 3 hour)]

    The incidence of significant apnea (>20seconds) %

  11. The lowest SpO2 value (%) [During pediatric procedural sedation (up to 3 hour)]

    The lowest SpO2 value (%)

  12. The incidence of hemodynamic intervention: fluid management, intravenous medication % [During pediatric procedural sedation (up to 3 hour)]

    The incidence of hemodynamic intervention: fluid management, intravenous medication %

  13. The incidence of significant bradycardia (-30% from baseline) % [During pediatric procedural sedation (up to 3 hour)]

    The incidence of significant bradycardia (-30% from baseline) %

  14. The incidence of significant hypotension (-30% from baseline) % [During pediatric procedural sedation (up to 3 hour)]

    The incidence of significant hypotension (-30% from baseline) %

  15. Patients' acceptance (1=excellent, 2=good, 3=fair, 4=poor) [During pediatric procedural sedation (up to 3 hour)]

    Patients' acceptance (1=excellent, 2=good, 3=fair, 4=poor)

  16. Separation anxiety (1=easy, 2=whimper, 3=cry, 4=cry and cling to parents) [During pediatric procedural sedation (up to 3 hour)]

    Separation anxiety (1=easy, 2=whimper, 3=cry, 4=cry and cling to parents)

  17. Physicians' satisfaction (1=excellent, 2=good, 3=fair, 4=poor) [During pediatric procedural sedation (up to 3 hour)]

    Physicians' satisfaction (1=excellent, 2=good, 3=fair, 4=poor)

  18. The incidence of other side effects (Ex: Nausea/Vomit, Allergic reaction, Etc) [During pediatric procedural sedation (up to 3 hour)]

    Other side effects (Ex: Nausea/Vomit, Allergic reaction, Etc)

  19. The incidence of failure of adequate sedation (PSSS= 0, 4,5) after 30 min % [During pediatric procedural sedation (up to 3 hour)]

    Failure of adequate sedation (PSSS= 0, 4,5) after 30 min %

  20. The incidence of completion of procedure [During pediatric procedural sedation (up to 3 hour)]

    Completion of procedure

  21. Total cost of sedation (KRW) [During pediatric procedural sedation (up to 1 day)]

    Total cost of sedation (KRW)

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 7 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Pediatric patients who need procedural sedation (Age < 7 years)

  • ASA (American Society of Anesthesiologists) physical status 1-3

Exclusion Criteria:
  • ASA (American Society of Anesthesiologists) physical status 4-5

  • History of hypersensitivity to Dexmedetomidine, Ketamine, or Chloral hydrate

  • Recent administration of Alpha 2 adrenergic receptor agonist or antagonist

  • Cannot administrate oral medication (e.g. Swallowing difficulty)

  • Cannot administrate intranasal medication(e.g. Excessive rhinorrhea)

  • Unstable vital signs, Unstable arrhythmia

Contacts and Locations

Locations

Site City State Country Postal Code
1 Jin-Tae Kim Seoul Korea, Republic of

Sponsors and Collaborators

  • Seoul National University Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jin-Tae Kim, Professor, Seoul National University Hospital
ClinicalTrials.gov Identifier:
NCT04820205
Other Study ID Numbers:
  • IN DEXKET first
First Posted:
Mar 29, 2021
Last Update Posted:
May 9, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jin-Tae Kim, Professor, Seoul National University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 9, 2022